KL and chronic kidney disease: The superiority of losartan (ARB) has been documented not only in an earlier study in animals with subtotal nephrectomy (Fujihara et al., 2005) but also in a recent study (Maquigussa et al., 2018) showing the ability of losartan to restore anti-fibrotic molecules Klotho and PPAR gamma and thus to reduce tubulointerstitial fibrosis which is one of the key factors underlying the progression of CKD to ESRD (Zoja et al., 2006).